

11th ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE

“Recent Advances and New Directions in Cancer Therapy”



Presented by the California Cancer Consortium

University of California Davis Comprehensive Cancer Center
SACRAMENTO, CA

City of Hope Comprehensive Cancer Center
DUARTE, CA

University of Southern California/Norris Comprehensive Cancer Center
LOS ANGELES, CA

University of Pittsburgh Cancer Institute/UPMC
PITTSBURGH, PA

Barbara Ann Karmanos Comprehensive Cancer Center (Wayne State University)
DETROIT, MI

Penn State Hershey Cancer Institute (Penn State University)
HERSHEY, PA

Educational Steering Committee and Conference Chairs:

Primo Lara, Jr., M.D. | Edward Newman, Ph.D.
Robert Morgan, M.D.

Sponsored by:

THE MEDICAL EDUCATOR
CONSORTIUM



EDUCATIONAL STEERING COMMITTEE & CONFERENCE CHAIRS

Primo Lara, Jr., M.D.

Professor of Medicine
University of California Davis
School of Medicine
Associate Director for Translational Research
University of California Davis
Comprehensive Cancer Center
Sacramento, CA

Edward Newman, Ph.D.

Associate Professor, Cancer Biology
Developmental Cancer Therapeutics
Program Co-Leader
City of Hope Comprehensive
Cancer Center
Duarte, CA

Robert Morgan, M.D.

Professor of Medicine, Department of
Medical Oncology and Therapeutics Research
Co-director, Gynecological Cancers Program
City of Hope Comprehensive Cancer Center,
Duarte, CA

Preet M. Chaudhary, M.D., Ph.D.

Chief, Jane Anne Nohl Division of
Hematology and Center for the Study
of Blood Diseases
Professor of Medicine, Ronald H. Bloom
Family Chair in Lymphoma Research
Program Director, USC/Norris Blood and
Marrow Transplant Program
Co-leader, Molecular Genetics Program,
Norris Comprehensive Cancer Center
Keck School of Medicine of USC,
University of Southern California
Los Angeles, CA

Helen Chew, M.D.

Professor of Medicine, Division
of Hematology/Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA

Mihaela Cristea, M.D.

Associate Clinical Professor, Medical
Oncology, Lung Cancer and Thoracic
Oncology Program
Gynecologic Oncology, Gynecological
Oncology/Peritoneal Malignancy Program
City of Hope Comprehensive Cancer Center
Duarte, CA

Savita Dandapani, M.D.

Assistant Professor, Radiation Oncology
City of Hope Comprehensive Cancer Center
Duarte, CA

Tanya Dorff, M.D.

Assistant Professor
University of Southern California
Keck School of Medicine, USC Norris
Comprehensive Cancer Center
Los Angeles, CA

Anthony El-Khoueiry, M.D.

Assistant Professor, University of Southern
California Keck School of Medicine
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Marwan Fakhri, M.D.

Interim Chair and Professor,
Medical Oncology and Therapeutics Research
Section Head, GI Medical Oncology
Co-Director, GI Cancers Program
City of Hope Comprehensive
Cancer Center
Duarte, CA

Agustin Garcia, M.D., MMM

Professor of Medicine
Section Chief of Hematology/Oncology
Louisiana State University
New Orleans, LA

Barbara J. Gitlitz, M.D.

Associate Professor of Medicine, USC Keck
School of Medicine
Los Angeles, CA

Susan Groshen, Ph.D.

Professor of Research, Department
of Preventive Medicine, University
of Southern California, USC Norris
Comprehensive Cancer Center
Los Angeles, CA

Elisabeth I. Heath, M.D., FACP

Hartmann Endowed Chair for Prostate
Cancer Research, Professor of Oncology
and Medicine, Director, Prostate Cancer
Research, Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, MI

James Hu, M.D.

University of Southern California
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Syma Iqbal, M.D., FACP

Associate Professor of Clinical Medicine
Program Director, Medical Oncology
Fellowship USC/Keck School of Medicine,
USC Norris Comprehensive Cancer Center
Division of Medical Oncology
Los Angeles, CA

Brian Jonas, M.D., Ph.D.

Assistant Professor of Medicine, Division
of Hematology/Oncology, UC Davis
Comprehensive Cancer Center
Sacramento, CA

Michael Kahn, Ph.D.

Professor of Biochemistry and
Molecular Biology
Provost's Professor of Medicine
and Pharmacy
Co-Chair, GI Oncology Program
USC Norris Comprehensive Cancer Center
USC Center for Molecular Pathways
and Drug Discovery
Los Angeles, CA

Karen Kelly, M.D.

Professor of Medicine
Associate Director for Clinical Research
Jennifer Rene Harmon Tegley and Elizabeth
Erica Harmon Endowed Chair in Cancer
Clinical Research
UC Davis Comprehensive Cancer Center,
Sacramento, CA

Kevin Kelly, M.D., Ph.D.

Associate Professor of Clinical Medicine
Assistant Medical Director of Clinical
Investigations Support Office, Jane Anne Nohl
Division of Hematology and Center for the
Study of Blood Diseases, University of
Southern California
Los Angeles, CA

DISTINGUISHED FACULTY

Edwin Alvarez, M.D.

Assistant Professor, Department
of Obstetrics and Gynecology
Division of Gynecologic Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA

Afsaneh Barzi, M.D., Ph.D.

Assistant Professor of Medical Oncology,
Department of Medicine, Division of Oncology
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Chandra Belani, M.D.

Miriam Beckner Distinguished
Professor of Medicine, Penn State
Milton S. Hershey Medical Center
Deputy Director and Associate Director
of Clinical Research, Penn State Hershey
Cancer Institute
Hershey, PA

M. Suzette Blanchard, Ph.D.

Associate Research Professor, Division of
Biostatistics, City of Hope Comprehensive
Cancer Center
Duarte, CA

Edward Kim, M.D., Ph.D.

Assistant Professor, Division of Hematology and Oncology
UC Davis Comprehensive Cancer Center,
Sacramento, CA

Marianna Koczywas, M.D.

Clinical Professor
City of Hope
Department of Medical Oncology and
Therapeutics Research
Thoracic Oncology and Lung
Cancer Program
Duarte, CA

Shivaani Kummar, M.D.

Professor, Department of Medicine
Director, Phase I Clinical Research Program
Stanford University School of Medicine
Stanford, CA

Primo N. Lara, Jr., M.D.

Professor of Medicine, UC Davis
School of Medicine
Associate Director for Translational Research,
UC Davis Comprehensive Cancer Center
Sacramento, CA

Heinz-Josef Lenz, M.D., Ph.D.

Professor of Medicine and Preventive Medicine/
Section Head of GI Oncology, University of
Southern California Keck School of Medicine
Associate Director for Clinical Research
USC Norris Comprehensive Cancer Center
Los Angeles, CA

Jeffrey Longmate, Ph.D.

Professor and Director Division of
Biostatistics, Department of Information
Sciences Beckman Research Institute/City of
Hope Comprehensive Cancer Center
Duarte, CA

Philip C. Mack, Ph.D.

Associate Adjunct Professor
UC Davis Comprehensive Cancer Center
Sacramento, CA

Robert Morgan, M.D.

Professor of Medicine, Department of Medical
Oncology and Therapeutics Research
Co-director, Gynecological Cancers Program
City of Hope Comprehensive Cancer Center
Duarte, CA

Edward Newman, Ph.D.

Associate Professor, Cancer Biology
Developmental Cancer Therapeutics
Program Co-Leader
City of Hope Comprehensive Cancer Center
Duarte, CA

Philip Philip, M.D.

Professor of Medicine, Wayne State University
School of Medicine, Detroit, MI
Clinical Professor of Oncology, Barbara Ann
Karmanos Cancer Institute
Detroit, MI

Leslie Popplewell, M.D., FACP

Hematology and Hematopoietic Cell
Transplantation
City of Hope Comprehensive Cancer Center
Duarte, CA

David Quinn, MBBS, Ph.D.

Associate Professor and Head Section of
GU Medical Oncology, USC Keck School
of Medicine, Los Angeles, CA; Leader
Developmental Therapeutics Program, USC
Norris Comprehensive Cancer Center
Los Angeles, CA

Jonathan W. Riess, M.D., MS

Assistant Professor of Medicine, Division
of Hematology and Oncology, UC Davis
Comprehensive Cancer Center,
Sacramento, CA

Steven T. Rosen, M.D.

Provost & Chief Scientific Officer
Director, Comprehensive Cancer Center and
Beckman Research Institute
Irell & Manella Cancer Center Director's
Distinguished Chair, City of Hope
Comprehensive Cancer Center
Duarte, CA

Sarmad Sadeghi, M.D., Ph.D.

Assistant Professor, University of Southern
California, Division of Oncology
USC Norris Comprehensive Cancer Center,
Los Angeles, CA

Thomas Semrad, M.D., MAS, FACP

Assistant Professor of Medicine
Division of Hematology and Oncology,
UC Davis Comprehensive Cancer Center
Sacramento, CA

Tanya Siddiqi, M.D.

Assistant Professor Department of Hematology
& Hematopoietic Cell Transplantation,
City of Hope National Medical Center,
City of Hope Comprehensive Cancer Center
Duarte, CA

George Somlo, M.D.

Professor, Department of Medical Oncology
and Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA

Cy A. Stein, M.D., Ph.D.

Professor, Department of Medical Oncology
Therapeutics Research
City of Hope Medical Center
Duarte, CA

Timothy Synold, Pharm.D.

Professor, Cancer Biology
Director, Analytical Pharmacology Core Facility
City of Hope Comprehensive Cancer Center
Duarte, CA

Ahmad Tarhini, M.D., Ph.D.

Associate Professor, Department of Medicine,
Hematology-Oncology
Clinical and Translational Science Institute,
University of Pittsburgh School of Medicine
Melanoma and Skin Cancer Program,
University of Pittsburgh Cancer Institute
UPMC Cancer Pavilion
Pittsburgh, PA

Joseph Tuscano, M.D.

Professor of Medicine
Division of Hematology and Oncology,
UC Davis School of Medicine/
UC Davis Comprehensive Cancer Center
Sacramento, CA

Przemyslaw Twardowski, M.D.

Clinical Professor of Medical Oncology,
City of Hope Medical Center
Duarte, CA

Ulka Vaishampayan, M.D.

Associate Professor of Medicine, Wayne State
University School of Medicine Barbara Ann
Karmanos Cancer Institute
Detroit, MI

Antoinette Wozniak, M.D.

Barbara Ann Karmanos Cancer Center
Detroit, MI

Hong Zheng, M.D., Ph.D.

Assistant Professor of Medicine
Division of Hematology/Oncology, Penn State
Hershey Cancer Institute
Penn State University College of Medicine
Hershey, PA

“Recent Advances and New Directions in Cancer Therapy”

COURSE DESCRIPTION

This conference aims to provide up-to-date information to the clinician regarding new advances in cancer biology, diagnosis, and treatment. It will bring together respected opinion leaders, practicing clinicians and scientists engaged in clinical cancer research to discuss the latest cancer diagnostic and therapeutic advances. Topics focus on the major cancers and drug development areas, including signal transduction/CDK inhibition, angiogenesis inhibition, PI3K/mTOR inhibition, antibody-drug conjugates, and immunotherapy, among others. This annual conference also includes interactive roundtable discussion forums with participation of cancer care experts from the California Cancer Consortium, and features renowned professionals from academia, patient advocacy, government, payer, industry, and business realms of cancer care.

EDUCATIONAL OBJECTIVES

After participating in this educational activity, you should be able to:

- Identify signaling and immunotherapeutic pathways that are involved in the growth and metastases of many individual tumor types, and identify specific opportunities for therapeutic intervention.
- Describe recent advances in the molecular phenotyping of cancer and relate these to the optimal management of your patients with cancer.
- Based on recent clinical trials, assess the efficacy of novel therapeutic strategies in the treatment of your patients with cancer.
- Discuss the new and emerging clinical trial designs that can test and validate new therapeutic strategies for cancer patients.

TARGET AUDIENCE

This program will be of interest to medical oncologists, hematologists, surgical oncologists, radiation oncologists, diagnostic radiologists, pulmonologists, urologists, gastroenterologists, pathologists, fellow and resident trainees, advanced care practitioners, registered nurses, physician assistants, clinical research coordinators, biostatisticians, and others involved in oncologic drug development and clinical care.

NEEDS ASSESSMENT

This course was developed in cooperation with the academic faculty and scientists belonging to the California Cancer Consortium to provide an annual in-depth exposure and review of new advances in cancer drug development, biology, biomarkers, diagnosis, and therapy. The agenda and format was

specifically designed to address knowledge gaps identified from prior course participant evaluations and unsolicited comments from practicing oncologists (from private practice, academia) as well as scientists involved in cancer clinical trials. This area of knowledge will be best addressed by an in-depth conference on systemic therapy of malignancies (both solid and hematologic), with ample time provided for interaction by attendees with expert faculty. It is expected that this course will enhance the clinical competence of clinicians in managing the care of the cancer patient, and subsequently improve patient outcomes.

ACCREDITATION

The Medical Educator Consortium is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT HOURS

The Medical Educator Consortium designates this educational activity for a maximum of 15 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE

The Medical Educator Consortium (MEC) adheres to the ACCME Standards for Commercial Support. All persons that will be in a position to control the content of the CME Activity are required to disclose all relevant financial relationships. Faculty disclosure forms outlining this information will be made available to all participants prior to educational activity. MEC has also implemented a mechanism to identify and resolve all conflicts of interest prior to the education activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.

NURSING CONTINUING MEDICAL EDUCATION

Continuing Medical Education is acceptable for meeting RN continuing education requirements, as long as the course is *AMA PRA Category 1 Credit(s)*[™], and has been taken within the appropriate time frames.

CONFERENCE AGENDA

11th Annual California Cancer Consortium Conference “Recent Advances and New Directions in Cancer Therapy”

FRIDAY, AUGUST 7th, 2015

11:00 am	Registration Opens & Visit Exhibits
12:00 - 1:00 pm	Lunch Symposia (non CME)
1:00 pm	Welcome and Introductions <i>Primo Lara, M.D. (UC Davis), Edward Newman, Ph.D. (City of Hope), Robert Morgan, M.D. (City of Hope)</i>
1:15 pm	SESSION 1: LUNG CANCER <i>Chair: Jonathan W. Riess (UC Davis)</i>
1:20 - 1:35 pm	Squamous Cell Lung Cancer: Emerging Developments <i>Marianna Koczywas, M.D. (City of Hope)</i>
1:35 - 1:40 pm	Question and Answer
1:40 - 1:55 pm	Non-Squamous Non-Small Cell Lung Cancer: Beyond EGFR and ALK <i>Chandra Belani, M.D. (Penn State University)</i>
1:55 - 2:00 pm	Question and Answer
2:00 - 2:15 pm	What's New in Small Cell Lung Cancer Therapeutics? <i>Antoinette Wozniak, M.D. (Karmanos Cancer Center)</i>
2:15 - 2:20 pm	Question and Answer
2:20 pm	SESSION 2: GENITOURINARY CANCERS (I) <i>Chair: Ulka Vaishampayan, M.D. (Karmanos Cancer Center)</i>
2:25 - 2:40 pm	Drug Development in Castration Resistant Prostate Cancer <i>Przemyslaw Twardowski, M.D. (City of Hope)</i>
2:40 - 2:45 pm	Question and Answer
2:45 - 3:00 pm	New Developments in Urothelial Cancer Therapeutics <i>Sarmad Sadeghi, M.D. (University of Southern California)</i>
3:00 - 3:05 pm	Question and Answer
3:05 - 3:20 pm	Refreshment Break, Visit Exhibits
3:20 pm	SESSION 3: GASTROINTESTINAL CANCERS (I) <i>Chair: Heinz Josef Lenz, M.D. (University of Southern California)</i>
3:20 - 3:35 pm	Hepatocellular and Hepatobiliary Cancers <i>Anthony El-Khoueiry, M.D. (University of Southern California)</i>
3:35 - 3:40 pm	Question and Answer
3:40 - 3:55 pm	Adenocarcinoma of the Pancreas: New Developments <i>Edward Kim, M.D. (UC Davis)</i>
3:55 - 4:00 pm	Question and Answer
4:00 pm	SESSION 4: NOVEL TARGETS IN ONCOLOGY DRUG DEVELOPMENT (I) <i>Chair: Barbara Gilitz, M.D. (University of Southern California)</i>
4:00 - 4:15 pm	Anti-mitotic Agents: Eribulin, Tubulin Inhibitors <i>David Quinn, M.D. (University of Southern California)</i>
4:15 - 4:30 pm	AR-V7 as a Target in Prostate Cancer <i>Cy A. Stein, M.D. (City of Hope)</i>
4:30 - 4:45 pm	Next-Generation EGFR Inhibitors <i>Jonathan Riess, M.D. (UC Davis)</i>
4:45 - 5:00 pm	Next-Generation Angiogenesis Inhibitors <i>Tanya Dorff, M.D. (University of Southern California)</i>
5:00 - 5:30 pm	PANEL DISCUSSION: Better Targets or Just Newer? <i>(Session Faculty)</i>
5:30 - 6:30 pm	Welcome Reception, Visit Exhibits

CONFERENCE AGENDA

SATURDAY, AUGUST 8th, 2015

- 7:00 am Registration & Visit Exhibits
7:00 - 8:00 am **Breakfast Symposium (non CME)**
8:00 am Welcome and Introductions
Primo Lara, M.D. (UC Davis), Edward Newman, Ph.D. (City of Hope), Robert Morgan, M.D. (City of Hope)
- 8:05 am **SESSION 5: INNOVATIVE CLINICAL TRIAL DESIGNS FOR THE GENOMIC ERA**
Chairs: Jeff Longmate, Ph.D. (City of Hope), Susan Grosben, Ph.D. (University of Southern California)
- 8:10 - 8:20 am Novel Dose Escalation Strategies
Jeff Longmate, Ph.D. (City of Hope)
8:20 - 8:30 am Biostatistical Considerations for Phase II Trials
Susan Grosben, Ph.D. (University of Southern California)
8:30 - 8:40 am Basket vs Umbrella Clinical Trials
M. Suzette Blanchard, Ph.D. (City of Hope)
8:40 - 9:05 am **PANEL DISCUSSION: Optimal Clinical Trial Designs**
Session Faculty
- 9:05 am **SESSION 6: HEMATOLOGIC MALIGNANCIES (I)**
Chair: Joseph Tuscano, M.D. (UC Davis)
- 9:10 - 9:25 am Novel Agents in Development for Acute Leukemia
Brian Jonas, M.D. (UC Davis)
9:25 - 9:30 am Question and Answer
9:30 - 9:45 am Chronic B- and T-cell Leukemias: New Developments
Kevin Kelly, M.D. (University of Southern California)
9:45 - 9:50 am Question and Answer
- 9:50 am **SESSION 7: GENITOURINARY CANCER (II)**
Chair: Primo Lara, Jr., M.D. (UC Davis)
- 9:55 - 10:10 am Renal Cell Cancer: New Agents in Development
Tanya Dorff, M.D. (University of Southern California)
10:10 - 10:15 am Question and Answer
10:15 - 10:30 am Prostate Cancer: New Therapeutics for the Pre-Castrate Resistant Prostate Cancer Patient
Elisabeth Heath, M.D. (Wayne State University)
10:30 - 10:35 am Question and Answer
10:35 - 10:50 am Refreshment Break, Visit Exhibits
- 10:50 am **SESSION 8: GASTROINTESTINAL CANCER (II)**
Chairs: Thomas Semrad, M.D. (UC Davis) Afaneh Barzi, M.D. (University of Southern California)
- 10:55 - 11:10 am Emerging Developments in Metastatic Colorectal Cancer
Syma Iqbal, M.D. (University of Southern California)
11:10 - 11:15 am Question and Answer
11:15 - 11:30 am State of the Art Management of Upper GI Tract Cancers (Gastric, GE Junction, Neuroendocrine Pancreatic Tumors)
Philip Philip, M.D. (Wayne State University)
11:30 - 11:35 am Question and Answer
- 11:35 am **SESSION 9: CANCER IMMUNOTHERAPY**
Chair: Leslie Popplewell, M.D. (City of Hope)
- 11:40 - 11:55 am Checkpoint Inhibitors: Current Status and Future Directions
Karen Kelly, M.D. (UC Davis)

CONFERENCE AGENDA

11:55 am - 12:00 pm Question and Answer
12:00 - 12:15 pm Cancer Vaccines and T-Cell Based Approaches
Mihaela Cristea, M.D. (City of Hope)

12:15 - 12:20 pm Question and Answer
12:20 - 12:35 pm Antibody-Drug Conjugates
Tanya Siddiqi, M.D. (City of Hope)

12:35 - 12:40 pm Question and Answer
12:40 - 1:20 pm *Lunch Symposia (non cme)*
1:20 - 1:35 pm Coffee & Dessert, Visit Exhibits

1:35 pm **SESSION 10: HEMATOLOGIC MALIGNANCIES (II)** *Chair: Leslie Popplewell, M.D. (City of Hope)*

1:40 - 1:55 pm New Molecular Agents for Malignant Lymphoma
Steven Rosen, M.D. (City of Hope)

1:55 - 2:00 pm Question and Answer
2:00 - 2:15 pm Multiple Myeloma: Latest and Greatest
Joseph Tuscano, M.D. (UC Davis)

2:15 - 2:20 pm Question and Answer
2:20 - 2:35 pm Follicular Lymphoma: Latest and Greatest
Hong Zheng, M.D. (Penn State University)
2:35 - 2:40 pm *Question and Answer*

2:40 pm **SESSION 11: GYNECOLOGIC CANCER** *Chair: Robert Morgan, M.D. (City of Hope)*

2:45 - 3:00 pm Refractory Ovarian Cancer: New Approaches
Agustin Garcia, M.D. (Louisiana State University)

3:00 - 3:05 pm Question and Answer
3:05 - 3:20 pm Endometrial and Cervix Cancers
Edwin Alvarez, M.D. (University of Southern California)

3:20 - 3:25 pm Question and Answer

3:25 - 3:40 pm **SESSION 12: BEST OF THE CALIFORNIA CANCER CONSORTIUM (II)** *Chair: Robert Morgan, M.D. (City of Hope)* *Fellow-led Presentation of CCC Research* *Presented by Jonathan W. Riess, M.D. & Thomas Semrad, M.D. (UC Davis)*

3:40 - 3:55 pm Refreshment Break, Visit Exhibits

3:55 pm **SESSION 13: CLINICAL AND MOLECULAR PHARMACOLOGY** *Co-Chairs: Edward Newman, M.D. (City of Hope)* *Tim Synold, M.D. (City of Hope)*

4:00 - 4:10 pm Optimizing Preclinical Cancer Models
Philip Mack, Ph.D. (UC Davis)

4:10 - 4:20 pm Specimen Collection and Molecular Phenotyping for Clinical Trials,
Circulating DNA

4:20 - 4:30 pm *Shivaani Kummar, M.D. (Stanford)*
Adaptive control: The Original Personalized Medicine
Tim Synold, Pharm.D. (City of Hope)

4:30 - 4:40 pm **PANEL DISCUSSION: Biomarker and PK Correlative Studies in the Era of Reduced Funding**
Session Faculty

5:10 pm Adjourn for Day

CONFERENCE AGENDA

SUNDAY, AUGUST 9th, 2015

7:00 am Registration, Visit Exhibits
7:00 - 8:00 am Breakfast Symposium (non cme)
8:00 am Welcome and Introductions
Primo Lara, M.D. (UC Davis), Edward Newman, Ph.D. (City of Hope), Robert Morgan, M.D. (City of Hope)

8:05 am **SESSION 15: NOVEL TARGETS IN ONCOLOGY DRUG DEVELOPMENT (II)**
Chair: Edward Newman, M.D. (City of Hope)

8:10 - 8:25 am Fibroblast Growth Factor Inhibitors
Thomas Semrad, M.D. (UC Davis)
8:25 - 8:40 am WNT signalling
Michael Kahn, M.D. (University of Southern California)
8:40 - 8:55 am Targeting DNA Repair: ADR Inhibitors (Radiosensitizers)
Savita Dandapani, M.D. (City of Hope)
8:55 - 9:10 am State of MEK Inhibitors in CRC
Marwan Fakih, M.D. (City of Hope)
9:10 - 9:25 am Question and Answer (session faculty)

9:25 am **SESSION 16: NEW DEVELOPMENTS IN HEMATOLOGY/ ONCOLOGY**
Chair: Primo Lara, M.D. (UC Davis)

9:30 - 9:45 am Malignant Melanoma: Latest and Greatest
Ahmad Tarhini, M.D. (University of Pittsburg)
9:45 - 9:50 am Question and Answer
9:50 - 10:05 am Targeted Drug Development for KSHV-Associated Malignancies
Preet M. Chaudhary, M.D. (University of Southern California)
10:05 - 10:10 am Question and Answer
10:10 - 10:25 am Refreshment Break, Visit Exhibits
10:25 - 10:40 am Soft Tissue Sarcoma: Latest and Greatest
James Hu, M.D. (University of Southern California)
10:40 - 10:45 am *Question and Answer*

10:45 am **SESSION 17: BREAST CANCER**
Co-chairs: George Somlo, M.D. (City of Hope), Helen Chew, M.D. (UC Davis)

10:50 - 11:05 am Emerging Treatments for Metastatic Triple Negative Breast Cancer
George Somlo, M.D. (City of Hope)
11:05 - 11:10 am Question and Answer
11:10 - 11:25 am HER2 Positive Breast Cancer: New Standards of Care
Helen Chew, M.D. (UC Davis)
11:25 - 11:30 am Question and Answer

11:30 - 11:55 am **SESSION 18: PANEL DISCUSSION:**
New Directions of the NCI in the Team Science Era
Faculty: Primo Lara, M.D. (UC Davis), Edward Newman, Ph.D. (City of Hope), Heinz Josef-Lenz, M.D. (City of Hope), Chandra Belani, M.D. (Penn State), Robert Morgan, M.D. (City of Hope)

11:55 am - 12:00 pm Closing Remarks and Adjourn

HOTEL INFORMATION



THE WESTIN PASADENA

191 N Los Robles Avenue
Pasadena, CA 91101

Reservation: 866.837.4181

The Westin Pasadena welcomes guests with a full complement of facilities and amenities, all designed to ensure you leave feeling better than when you arrived. We prioritize convenience and simplicity with our 24-hour Business Center, where you can put tasks behind you with ease, as well as Concierge services, for professional guidance on enjoying the best Pasadena has to offer. For reenergizing and clearing your mind, take advantage of our light-filled WestinWORKOUT® Fitness Studio and our alluring outdoor heated pool, with gorgeous views.

Enjoy some of the finest views of the San Gabriel Mountains and the Pasadena area from The Westin Pasadena, or step out to partake in the colorful spirit of downtown. Shoppers and food-lovers alike will revel in the remarkable range of options surrounding us. Just a few minutes on foot from the hotel, the Paseo Colorado features premier dining and retail outlets plus a cinema. Less than a mile away, historic Old Pasadena's charming storefronts house 200 shops plus a wide array of restaurants and night spots.

The Westin is located within walking distance of the Pacific Asia Museum areas, while the California Technical Institute, the historic Tournament of Roses house, and the Norton Simon Museum are all less than two miles away. A ten-minute drive will take you to the resplendent Huntington Library, with its extensive art collections and botanical gardens.

Golf enthusiasts will enjoy the 36-hole, William P. Bell-designed Brookside Golf Club, just a five-minute drive away. The nine-hole Eaton Canyon course is 15 minutes away in the San Gabriel foothills, and Santa Anita Park—a famous thoroughbred racetrack—is equally close by. The Rose Bowl, a world-famous sports and entertainment venue boasting beautiful greenery and cliff sides, is only five minutes away by car.

The Westin Pasadena is offering special rates during this conference of \$179 single or double room plus tax, European Plan (no meals). **The cutoff date to make reservations is July 6th, 2015, after this date reservations are subject to hotel availability.**

Make your hotel reservations by calling 866.837.4181 and use group code **“CA Cancer Consortium Conference”**

CONFERENCE MANAGEMENT

MEETING EVENTS & CONFERENCE COORDINATORS, INC (MECC)

1550 S Dixie Highway Suite 202

Coral Gables, FL 33146

Telephone: 305.663.1628

Fax: 305.675.2718

Website: www.meccinc.com

Email: tvalls@meccinc.com

Register online at www.meccinc.com under conference information and registration.

11th Annual California Cancer Consortium Conference

“Recent Advances and New Directions in Cancer Therapy”

August 7-9, 2015, The Westin Pasadena, Pasadena, CA

Registration Form

Name _____ Degree _____

License Number _____ State _____

Address _____

Telephone (____) _____ Fax (____) _____

Email _____

Specialty _____

TYPE OF PRACTICE:

- Private Academic
 Hospital Other

REGISTRATION FEE:

- \$175 Physician
 \$ 75 Nurse, Nurse Practitioner, Resident, Fellow,
Students, Non-physician researchers and staff
(e.g., CRAs)
 \$250 Industry Professional

Refunds must be provided in writing prior to July 6th, 2015. A \$50 administrative charge will be deducted for all refunds prior to July 6th, after July 6th no refunds will be provided.

I authorize MECC to charge my credit card i/a/o \$ _____ for the registration of this course using the following credit card.

Name as it appear on the card _____ Exp. Date _____

Card number _____ CVV Code: _____

Authorized signature _____

**For those requiring special assistance, contact MECC
at 305.663.1628 or via email tvalls@meccinc.com no later than July 6th, 2015.**

Meetings, Events and Conference Coordinators, Inc.
P.O. Box 430376
Miami, FL 33243-0376

PRST STD
US Postage
PAID
Miami, FL
Permit No. 1429

11th ANNUAL CALIFORNIA CANCER CONSORTIUM CONFERENCE
“Recent Advances and New Directions in Cancer Therapy”

August 7-9, 2015

The Westin Pasadena, Pasadena, CA